Cargando…
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
BACKGROUND: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. METHODS: We reviewed our d...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937609/ https://www.ncbi.nlm.nih.gov/pubmed/27388210 http://dx.doi.org/10.1186/s12885-016-2423-x |
_version_ | 1782441739469979648 |
---|---|
author | Lee, Eun-Shin Han, Wonshik Kim, Min Kyoon Kim, Jongjin Yoo, Tae-kyung Lee, Moo Hyun Lee, Kyung Hun Kim, Tae Yong Moon, Hyeong-Gon Im, Seock-Ah Noh, Dong-Young Lee, Eun Sook |
author_facet | Lee, Eun-Shin Han, Wonshik Kim, Min Kyoon Kim, Jongjin Yoo, Tae-kyung Lee, Moo Hyun Lee, Kyung Hun Kim, Tae Yong Moon, Hyeong-Gon Im, Seock-Ah Noh, Dong-Young Lee, Eun Sook |
author_sort | Lee, Eun-Shin |
collection | PubMed |
description | BACKGROUND: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. METHODS: We reviewed our database of ER-positive patients who had received operations between 1996 and 2006 in two institutions. We selected 444 who had completed 5-year tamoxifen and were disease-free up to 10 years after the operation. Patients who had received aromatase inhibitors with any regimens were excluded. As a late recurrence group, 139 patients were identified who had completed 5-year tamoxifen, but had recurrence afterwards. Among them, 61 had local/contralateral breast recurrence and 78 had distant metastasis. The median follow-up was 9.7 years. Clinicopathological factors at the time of initial operation, such as age, menopausal status, progesterone receptor expression, HER2 status, tumor grade and Ki-67, were compared between the disease-free group and the late recurrence group. RESULTS: In a univariate analysis, tumor size (>2 cm), lymph node metastasis and high histologic grade were significantly associated with late recurrences (p < 0.05). In a multivariate analysis, only axillary lymph node metastasis was significant (p < 0.001). Late distant metastasis was significantly associated with tumor size and axillary lymph node metastasis (p = 0.038, p < 0.001,respectively). Late local/contralateral breast recurrence was associated with axillary lymph node metastasis (p = 0.042). CONCLUSIONS: Our data showed axillary lymph node metastasis at initial operation was the only risk factor of late recurrence after completion of tamoxifen for 5 years. Our results can be helpful in making decisions to use extended tamoxifen beyond 5 years. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2423-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4937609 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49376092016-07-09 Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer Lee, Eun-Shin Han, Wonshik Kim, Min Kyoon Kim, Jongjin Yoo, Tae-kyung Lee, Moo Hyun Lee, Kyung Hun Kim, Tae Yong Moon, Hyeong-Gon Im, Seock-Ah Noh, Dong-Young Lee, Eun Sook BMC Cancer Research Article BACKGROUND: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. METHODS: We reviewed our database of ER-positive patients who had received operations between 1996 and 2006 in two institutions. We selected 444 who had completed 5-year tamoxifen and were disease-free up to 10 years after the operation. Patients who had received aromatase inhibitors with any regimens were excluded. As a late recurrence group, 139 patients were identified who had completed 5-year tamoxifen, but had recurrence afterwards. Among them, 61 had local/contralateral breast recurrence and 78 had distant metastasis. The median follow-up was 9.7 years. Clinicopathological factors at the time of initial operation, such as age, menopausal status, progesterone receptor expression, HER2 status, tumor grade and Ki-67, were compared between the disease-free group and the late recurrence group. RESULTS: In a univariate analysis, tumor size (>2 cm), lymph node metastasis and high histologic grade were significantly associated with late recurrences (p < 0.05). In a multivariate analysis, only axillary lymph node metastasis was significant (p < 0.001). Late distant metastasis was significantly associated with tumor size and axillary lymph node metastasis (p = 0.038, p < 0.001,respectively). Late local/contralateral breast recurrence was associated with axillary lymph node metastasis (p = 0.042). CONCLUSIONS: Our data showed axillary lymph node metastasis at initial operation was the only risk factor of late recurrence after completion of tamoxifen for 5 years. Our results can be helpful in making decisions to use extended tamoxifen beyond 5 years. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-016-2423-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-07 /pmc/articles/PMC4937609/ /pubmed/27388210 http://dx.doi.org/10.1186/s12885-016-2423-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Lee, Eun-Shin Han, Wonshik Kim, Min Kyoon Kim, Jongjin Yoo, Tae-kyung Lee, Moo Hyun Lee, Kyung Hun Kim, Tae Yong Moon, Hyeong-Gon Im, Seock-Ah Noh, Dong-Young Lee, Eun Sook Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
title | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
title_full | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
title_fullStr | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
title_full_unstemmed | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
title_short | Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
title_sort | factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937609/ https://www.ncbi.nlm.nih.gov/pubmed/27388210 http://dx.doi.org/10.1186/s12885-016-2423-x |
work_keys_str_mv | AT leeeunshin factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT hanwonshik factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT kimminkyoon factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT kimjongjin factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT yootaekyung factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT leemoohyun factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT leekyunghun factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT kimtaeyong factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT moonhyeonggon factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT imseockah factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT nohdongyoung factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer AT leeeunsook factorsassociatedwithlaterecurrenceaftercompletionof5yearadjuvanttamoxifeninestrogenreceptorpositivebreastcancer |